Cosmos Health INC 8-K filings

Cosmos Health Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the approval of Series B Preferred Stock.

Cosmos Health Inc. announced its Board of Directors has authorized a share repurchase program of up to $5 million of its common stock, reflecting confidence in the company's fundamentals and growth prospects.

Cosmos Health reported record first-quarter revenue of $17.9 million, a 31% year-over-year increase, alongside a significant reduction in total liabilities.

Cosmos Health achieved record annual revenue of $65.3 million in 2025, representing a 20% year-over-year increase.

Cosmos Health Inc. received a non-compliance letter from Nasdaq for failing to maintain its minimum bid price, facing potential delisting.

Cosmos Health Inc. reported record third-quarter 2025 financial results, driven by significant revenue and gross profit growth across all core business segments and a strengthened cash position.

Cosmos Health Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Cosmos Health Inc. announced the immediate appointment of Theodoros C. Karkantzos to its Board of Directors and Nominating and Corporate Governance Committee.

Cosmos Health Inc. stockholders approved a significant increase in authorized shares and elected a new board of directors at their 2025 Annual Meeting.

Cosmos Health Inc. announced its CEO's annual letter detailing a $300 million digital asset financing facility, U.S. manufacturing expansion, and AI innovation for global healthcare growth.

Cosmos Health Inc. has secured an $8 million senior secured convertible promissory note due August 7, 2027, from an institutional investor, enhancing its financial flexibility.

Cosmos Health Inc. has secured a senior secured convertible promissory note facility of up to $300 million to fund its Ethereum digital asset treasury reserve strategy and general corporate purposes.

Cosmos Health has been granted an additional 180-day period to meet Nasdaq's minimum bid price requirement.

Cosmos Health Inc. announces it will delay its planned offering under Form S-1 until after the filing of its annual report for the fiscal year ended December 31, 2024.

Cosmos Health subsidiary CosmoFarm S.A. secured a $2.29 million secured bond from a European bank to support strategic growth initiatives and general corporate purposes.

Cosmos Health Inc. has entered into a licensing agreement for exclusive worldwide rights to commercialize cancer treatment patents, involving an initial payment, annual fees, and potential royalties.

Cosmos Health Inc. held its Annual Meeting of Shareholders on November 19, 2024, where key proposals including the election of directors, share issuance, ratification of the accounting firm, approval of an equity incentive plan, and authorization for reverse stock splits were approved.

Cosmos Health Inc. received a non-compliance notice from Nasdaq for failing to maintain a minimum share price of $1.00 for 30 consecutive days.

Cosmos Health Inc. has agreed to issue new warrants to Armistice Capital Master Fund Ltd. in exchange for the exercise of existing warrants, with the new warrants having an exercise price of $0.95 per share.

Cosmos Health has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Cosmos Health Inc. is facing potential delisting from Nasdaq due to the late filing of its annual and quarterly reports, alongside the dismissal of its previous auditor and disagreements over accounting practices.

Cosmos Health Inc. filed an amendment to its previous report detailing the dismissal of KPMG as its auditor, a disagreement over accounting practices, and the appointment of a new auditor, RBSM LLP.

Cosmos Health Inc. replaced its auditor, KPMG, with RBSM LLP following a dispute over accounting practices and the handling of a third-party consignment vendor transaction.

Cosmos Health Inc. has dismissed KPMG as its independent auditor due to their inability to complete the 2023 financial audit on time.

Cosmos Health Inc. has adopted a shareholder rights plan, also known as a 'poison pill', to protect shareholder interests against potential hostile takeovers.

Cosmos Health has received a notification from Nasdaq for failing to file its annual report on time, potentially leading to delisting if compliance is not regained.

Cosmos Health Inc. received a non-compliance notice from Nasdaq for failing to maintain a minimum share price and formalized its related party transaction policy.

Cosmos Health has completed the acquisition of a portfolio of 10 generic drugs for $3.5 million, enhancing its pharmaceutical offerings and market reach.